Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHOLEDYL vs Fluoxetine-Safety-Postpartum
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Choledyl is a salt of theophylline (1,3-dimethylxanthine) and choline. Theophylline acts as a bronchodilator by inhibiting phosphodiesterase (PDE) and antagonizing adenosine receptors, resulting in increased intracellular c AMP and smooth muscle relaxation. It also enhances respiratory drive and diaphragm contractility.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.
Treatment of bronchial asthma,Treatment of reversible bronchospasm associated with chronic bronchitis and emphysema
Major depressive disorder,Obsessive-compulsive disorder,Bulimia nervosa,Panic disorder,Premenstrual dysphoric disorder (off-label),Bipolar depression (off-label),Social anxiety disorder (off-label)
200-400 mg orally 4 times daily, not to exceed 2.4 g/day; or as sustained-release tablets: 400-600 mg twice daily.
20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.
Terminal elimination half-life: 7-9 hours (non-smoking adults); 4-5 hours (smokers); 20-30 hours (premature neonates, hepatic cirrhosis, CHF); clinical context: dose adjustment required for smokers and hepatic impairment.
Fluoxetine: 4-6 days (acute), 4-6 weeks (chronic); norfluoxetine: 4-16 days. Steady-state achieved after 2-4 weeks.
Primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP1A2, with minor contributions from CYP2E1 and CYP3A4.
Hepatic via CYP2D6, CYP2C9, CYP3A4; active metabolite norfluoxetine.
Primarily renal excretion of theophylline metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid), with 10% unchanged drug; biliary/fecal < 5%.
Renal (80% as metabolites, 10% as unchanged drug) and fecal (15%)
40% bound, primarily to albumin.
94% bound to albumin and alpha-1-acid glycoprotein
Vd: 0.5 L/kg (0.3-0.7 L/kg); clinical meaning: distributes into total body water, with higher volume in premature neonates.
12-43 L/kg; extensive tissue distribution including brain, breast milk.
Oral immediate-release: 100%; oral sustained-release: 85-95%; rectal: 90-100% (variable).
Oral: 95% (72% after first-pass); food may slightly decrease rate but not extent.
GFR 30-50 m L/min: reduce dose by 50%; GFR <30 m L/min: administer 200 mg every 12-24 hours; consider monitoring serum theophylline levels.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). For severe renal impairment (GFR <30 m L/min), use cautiously with a maximum dose of 40 mg/day.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 75%; Child-Pugh C: contraindicated or reduce dose by 90% with close monitoring of serum levels.
Child-Pugh Class A: 20 mg every other day; Class B: 20 mg every third day; Class C: avoid use or use 10 mg every third day with careful monitoring.
Not recommended for children under 6 years; for children 6-12 years: 10-12 mg/kg/day divided every 6-8 hours; for adolescents: same as adult dosing, adjusted based on serum levels.
Children (8-12 years): 10-20 mg orally once daily; adolescents (13-17 years): 20 mg orally once daily. Maximum 60 mg/day. Weight-based: 0.5-1.0 mg/kg/day, titrate to maximum 1.5 mg/kg/day.
Start at 200 mg twice daily; adjust based on serum theophylline levels (target 5-15 mcg/m L); monitor for toxicity due to reduced clearance.
Initial dose 10 mg orally once daily; titrate slowly to a maximum of 40 mg/day due to increased half-life and risk of hyponatremia and QT prolongation.
No FDA black box warning.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Risk of toxicity due to narrow therapeutic index; serum levels should be monitored carefully.,Use with caution in patients with peptic ulcer, cardiac arrhythmias, seizure disorders, or hyperthyroidism.,May exacerbate gastroesophageal reflux disease.,Concomitant use with other xanthine derivatives may increase toxicity.
Serotonin syndrome; risk of bleeding; activation of mania/hypomania; hyponatremia; discontinuation syndrome; QT prolongation (overdose).
Hypersensitivity to theophylline or choline salicylate,Active peptic ulcer disease,Seizure disorder (unless appropriately controlled)
Concurrent use with MAOIs (or within 14 days); concurrent use with thioridazine or pimozide; known hypersensitivity to fluoxetine.
High-fat meals may increase absorption; avoid charbroiled meats which decrease theophylline clearance. Consistent caffeine intake should be maintained to avoid fluctuations in drug levels.
No specific food interactions; avoid grapefruit juice as it may increase fluoxetine levels. Take with or without food; if GI upset occurs, take with food.
Choledyl (theophylline oxtriphylline) is a xanthine derivative. In pregnancy, theophylline crosses the placenta. First trimester: No consistent evidence of major malformations, but some studies suggest a small increased risk of congenital heart defects. Second and third trimesters: Fetal tachycardia, jitteriness, and hypoglycemia can occur with maternal high levels. Neonatal withdrawal and respiratory distress have been reported.
First trimester: Exposure associated with a small increased risk of cardiovascular malformations, primarily ventricular septal defects (absolute risk ~2-3% vs 1% baseline). Second/third trimester: Persistent pulmonary hypertension of the newborn (PPHN) risk ~1.5-2 times baseline; risk of preterm birth and low birth weight. Late third trimester: Risk of poor neonatal adaptation syndrome (PNAS) including jitteriness, respiratory distress, feeding difficulties, and irritability.
Theophylline is excreted into breast milk. Milk-to-plasma ratio is approximately 0.6-0.7. Concentrations in milk can reach 60-70% of maternal serum levels. Infant exposure may cause irritability, jitteriness, and poor feeding. Use with caution, monitor infant for adverse effects, and consider timing doses after breastfeeding.
Fluoxetine and its active metabolite norfluoxetine are excreted into breast milk; M/P ratio ~0.3-1.0 for fluoxetine and ~0.5-2.0 for norfluoxetine. Relative infant dose approximately 2-12% of maternal weight-adjusted dose. Cases of colic, irritability, and poor feeding in breastfed infants have been reported. Generally considered compatible with breastfeeding; however, monitor infant for sedation, poor weight gain, and development.
During pregnancy, theophylline clearance may decrease due to reduced hepatic metabolism and increased plasma volume. Dose adjustments are often required, especially in the third trimester. Monitor serum levels closely, as clearance can decrease by 20-30%. Dose may need to be reduced by 20-30% to maintain therapeutic levels. Postpartum, clearance returns to prepregnancy levels, requiring dose increase.
Pregnancy increases fluoxetine clearance and decreases plasma concentrations, especially in the third trimester. Dose may need to be increased by 20-50% (e.g., from 20 mg to 30-40 mg daily) to maintain therapeutic effect. Consider therapeutic drug monitoring if available. Postpartum, dose should be reduced to pre-pregnancy levels within 48-72 hours due to reversal of pharmacokinetic changes.
Choledyl (oxtriphylline) is a bronchodilator; monitor theophylline levels due to narrow therapeutic index. Avoid in patients with peptic ulcer or seizure disorders. Cautious use with hepatic impairment or heart failure. Dose adjustment needed with cimetidine, ciprofloxacin, or macrolides due to decreased clearance.
Fluoxetine has a long half-life (4-6 days, norfluoxetine 4-16 days) resulting in steady-state after 2-4 weeks; use lower starting doses (10 mg daily) in postpartum women to minimize side effects; monitor for neonatal adaptation syndrome if used in third trimester; consider dose adjustment in hepatic impairment; avoid in breastfeeding unless benefit outweighs risk due to presence in breast milk.
Take with food if GI upset occurs.,Avoid excessive caffeine (coffee, tea, cola) as it may increase side effects.,Do not crush or chew sustained-release forms.,Seek medical attention for rapid heartbeat, seizures, or severe nausea.,Report signs of toxicity: persistent vomiting, confusion, or palpitations.
Take fluoxetine exactly as prescribed, typically once daily in the morning.,It may take 4 weeks or longer to feel full benefit; do not stop abruptly.,Common side effects include nausea, headache, insomnia, and sexual dysfunction.,Contact your doctor if you experience rash, unusual bleeding, or suicidal thoughts.,Avoid alcohol while taking this medication.,Do not breastfeed without discussing risks with your healthcare provider.
No interactions on record
"Pazopanib, a tyrosine kinase inhibitor, inhibits CYP2D6 activity, leading to reduced metabolism of fluoxetine, a substrate of CYP2D6. This results in increased serum concentrations of fluoxetine and its active metabolite norfluoxetine, elevating the risk of serotonin-related adverse effects such as serotonin syndrome, nausea, and insomnia. The interaction is clinically significant and may require dose adjustment of fluoxetine."
"Concurrent administration of etomidate and fluoxetine may potentiate the anesthetic and sedative effects, as fluoxetine inhibits CYP3A4 which is involved in the metabolism of etomidate, leading to increased etomidate plasma concentrations and prolonged recovery time. Additionally, both drugs can cause QTc interval prolongation, increasing the risk of torsades de pointes and other ventricular arrhythmias. Patients may experience enhanced central nervous system depression, respiratory depression, and hypotension."
"Concomitant use of tolcapone, a catechol-O-methyltransferase (COMT) inhibitor used in Parkinson's disease, with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), may potentiate serotonergic effects leading to serotonin syndrome, characterized by autonomic instability, neuromuscular hyperactivity, and altered mental status. Additionally, both drugs undergo hepatic metabolism via CYP450 enzymes, and fluoxetine's inhibition of CYP2C9 and CYP3A4 may reduce tolcapone clearance, increasing the risk of hepatotoxicity and other adverse effects. The combination requires careful monitoring for signs of serotonin toxicity and liver injury."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHOLEDYL vs Fluoxetine-Safety-Postpartum, answered by our medical review team.
CHOLEDYL is a Bronchodilator that works by Choledyl is a salt of theophylline (1,3-dimethylxanthine) and choline. Theophylline acts as a bronchodilator by inhibiting phosphodiesterase (PDE) and antagonizing adenosine receptors, resulting in increased intracellular c AMP and smooth muscle relaxation. It also enhances respiratory drive and diaphragm contractility.. Fluoxetine-Safety-Postpartum is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHOLEDYL and Fluoxetine-Safety-Postpartum depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHOLEDYL is: 200-400 mg orally 4 times daily, not to exceed 2.4 g/day; or as sustained-release tablets: 400-600 mg twice daily.. The standard adult dose of Fluoxetine-Safety-Postpartum is: 20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHOLEDYL and Fluoxetine-Safety-Postpartum in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHOLEDYL is classified as Category C. Choledyl (theophylline oxtriphylline) is a xanthine derivative. In pregnancy, theophylline crosses the placenta. First trimester: No consistent evidence of major malformations, but. Fluoxetine-Safety-Postpartum is classified as Category A/B. First trimester: Exposure associated with a small increased risk of cardiovascular malformations, primarily ventricular septal defects (absolute risk ~2-3% vs 1% baseline). Second/. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.